VCM
ADMA icon

Viewpoint Capital Management’s ADMA Biologics ADMA Stock Holding History

Viewpoint Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,416
Closed -$228K – 141
2024
Q2 		$228K Buy
20,416
+5,000
+32% +$41.9K 0.14% 97
2024
Q1 		$102K Buy
15,416
+2,416
+19% +$13.2K 0.06% 110
2023
Q4 		$58.8K Hold
13,000
– – 0.04% 112
2023
Q3 		$46.5K Hold
13,000
– – 0.04% 108
2023
Q2 		$48K Hold
13,000
– – 0.04% 109
2023
Q1 		$43K Hold
13,000
– – 0.04% 100
2022
Q4 		$50.4K Buy
+13,000
New +$40.1K 0.05% 98
2022
Q3 		– Sell
-13,000
Closed -$26K – 110
2022
Q2 		$26K Buy
+13,000
New +$25.6K 0.02% 103

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Viewpoint Capital Management's ADMA Position: Q3 2024 in Review

Viewpoint Capital Management sold out of ADMA Biologics (ADMA) in Q3 2024, closing a stake of 20,416 shares — an estimated $228K sold.

Viewpoint Capital Management first reported a position in ADMA in Q2 2022 and held it in 8 quarters. The position peaked at $228K in Q2 2024. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

  • Viewpoint Capital Management reported no remaining ADMA Biologics position as of Q3 2024 after selling out during the quarter.
  • Viewpoint Capital Management sold 20,416 ADMA Biologics shares in Q3 2024, an estimated $228K.
  • Viewpoint Capital Management first reported a position in ADMA Biologics in Q2 2022 and held it in 8 quarters.
  • Viewpoint Capital Management's ADMA Biologics position peaked at $228K in Q2 2024.
  • 306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Viewpoint Capital Management's 13F filing for Q3 2024, filed 24 Oct 2024.